Logotype for Dyadic International Inc

Dyadic International (DYAI) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dyadic International Inc

Q3 2026 earnings summary

13 Nov, 2026

Executive summary

  • First direct commercial sales of recombinant transferrin and DNase I established a new product revenue channel, though initial sales were not material; partner launches and distribution also advanced.

  • Commercialization remains slower than planned as customer qualification takes longer, while strategy emphasizes partnerships, licensing and supply agreements to scale with less capital investment.

  • C1 biopharma programs advanced into preclinical animal studies, but substantial doubt about the ability to continue as a going concern and constrained financing remain central concerns.

Financial highlights

  • Q3 revenue was $449,101, down 61.4% YoY from $1.16 million, primarily due to lower grant and R&D collaboration revenue; 9M revenue was $2.52 million, essentially flat YoY.

  • Q3 revenue comprised $276,372 in grants, $162,318 in R&D revenue and $10,411 in license and milestone revenue; 9M grant revenue was $1.60 million.

  • Q3 operating loss was $1.81 million versus $1.93 million; net loss was $1.36 million, or $0.04/share, versus $1.98 million, or $0.06/share.

  • 9M operating loss was $5.77 million versus $5.66 million; net loss was $5.44 million, or $0.15/share, versus $5.80 million, or $0.18/share.

  • Q3 cost of revenue fell 63.4% to $375,115; internal R&D expense fell 24.8% to $429,945 and G&A fell 2.1% to $1.45 million.

Outlook and guidance

  • The $225,000 Inzymes milestone for the October commercial sale of Dapibus-produced camel chymosin is expected to be recognized as Q4 2026 revenue.

  • Gates-funded RSV and malaria antibody animal-study results are expected in Q1 2027; further development depends on results and external funding.

  • Management expects operating losses and negative operating cash flows to continue; unrestricted cash, cash equivalents and investments, net of unpaid offering costs, were expected to fund operations for seven months at the 9M cash-use rate.

  • Financing, grant funding, expanded product sales, licensing, partnerships and supply arrangements are being pursued, with execution and timing uncertain.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Dyadic International